Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.
about
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignImpact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationThe hepatitis C virus glycan shield and evasion of the humoral immune responseNeutralizing antibody response to hepatitis C virusHepatitis C Virus E2 Envelope Glycoprotein Core StructureThe impact of hepatitis C virus entry on viral tropismMechanisms of viral mutationImmunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virusAnalysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolutionThe core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigsAdaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.Regulated Entry of Hepatitis C Virus into Hepatocytes.Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423Immune control and failure in HCV infection--tipping the balance.Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles.Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agentsSpecific acquisition of functional CD59 but not CD46 or CD55 by hepatitis C virus.The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins.Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing.Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralizationReproduction in vitro of a quasispecies from a hepatitis C virus-infected patient and determination of factors that influence selection of a dominant species.Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.Hepatitis C virus life cycle and lipid metabolismNeutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans.Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodiesProduction and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a InfectionA human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion.Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region
P2860
Q26801759-41D622EF-A617-463B-B09E-358D6A72C584Q26864485-510B836F-31DC-45C6-908A-5B0AB7FF7A10Q27023390-FD6CFBDB-5A1C-4D12-B739-FDA72488FC78Q27027484-4E7A4F07-851E-446A-8FFB-0086B17E4333Q27680704-871959BB-6CC2-4032-9CC1-94109447587AQ27693297-967E3A59-4115-4220-8D4D-9E18F2E90388Q28067235-0B9990C0-D73F-498B-8AF0-1DDA28B84D52Q28604286-9FFEA2C3-732E-4B9D-8450-C3FFA2A46423Q28659586-81255970-8786-445E-BADD-D447133DBDECQ33612608-58C4746B-D8F5-46F1-B3C8-ACC23D7B48E1Q33628805-7C144365-A68E-487B-9F0D-0A50A1605876Q33753913-2D3BE17E-535C-48B7-8061-59E0DD3AE82BQ33890011-2F8AB02A-8EF3-4000-B2CC-6A90C9369536Q34047477-C42BCA81-E9C7-419F-AAC4-E32E62266611Q34178628-762C2715-1B74-45D6-9E39-0C0AA9144A60Q34262165-1563697E-22B9-4092-952D-D43B4419E6EEQ34262175-F7FFFCC6-FB7F-4A39-81CB-DE2A8904115BQ34387277-84A3BEC1-6E49-4E6B-835C-C8A8195CE1BCQ34416004-CAB85EAA-7BE4-4672-A942-68313689FB7EQ34438382-FB1A32CD-5DA6-48F2-B1E4-90C6BBA7E140Q34481429-E5D29CD6-7DC2-4F92-AA57-0C53F22692A4Q34540988-8322A48C-504B-417D-B1C6-B5CE4653FCA6Q34594027-586CC1C6-D943-4889-8A84-40E9E0BF8641Q34741652-E58AD065-DED4-4B64-A99E-0CA2EE7FF9E6Q34742576-77DEAB36-CA64-4E1B-AE79-0F28F9DCA652Q34742954-545CDB90-7548-44DC-85BC-146B844BD307Q34792436-7F3AC0AA-4FEF-486E-AAC2-49BA83358266Q35231331-D569AD00-616C-41BF-A392-FFED16A2B8CAQ35450992-C2B2049C-7D42-4D4B-AAC4-5C2F299F5199Q35488198-E472FE83-0D49-45B1-8055-ECE53218940DQ35557495-6127F562-CA08-4CEA-A7CB-9D1475B9264FQ35557533-22011629-9A19-497C-A5D9-E132893B40EEQ35630492-E97B8666-BC53-48E6-BB83-6523C8273E6FQ35685409-99465838-7042-429B-AF55-F51A4754DB2EQ35861270-6EEDF764-2DCE-417A-9138-71D2968325AAQ35914270-444E0387-41F0-4957-BD52-9F1089100701Q36133495-C5494611-46D1-4E67-A825-E6A3BD33DC73Q36288404-F5BD804A-F081-4832-8C4E-07D6BEBBF782Q36318779-35DC18B5-5D43-4442-8D99-97A4449EFC45Q36334312-39A27246-6D76-4761-988C-2F1D7C0AA42E
P2860
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Hepatitis C virus hypervariabl ...... nserved neutralizing epitopes.
@ast
Hepatitis C virus hypervariabl ...... nserved neutralizing epitopes.
@en
type
label
Hepatitis C virus hypervariabl ...... nserved neutralizing epitopes.
@ast
Hepatitis C virus hypervariabl ...... nserved neutralizing epitopes.
@en
prefLabel
Hepatitis C virus hypervariabl ...... nserved neutralizing epitopes.
@ast
Hepatitis C virus hypervariabl ...... nserved neutralizing epitopes.
@en
P2093
P2860
P356
P1433
P1476
Hepatitis C virus hypervariabl ...... onserved neutralizing epitopes
@en
P2093
Dorothea Bankwitz
Eva Herrmann
Eve-Isabelle Pécheur
Julia Bitzegeio
Martina Friesland
Sandra Ciesek
Steven K H Foung
Thomas F Baumert
Thomas Pietschmann
Zhen-yong Keck
P2860
P304
P356
10.1128/JVI.02200-09
P577
2010-03-31T00:00:00Z